



September 12, 2024

Company name	CellSource Co., Ltd.
Name of representative	Takashi Sawada, Representative Director and CEO
Securities code	Tokyo Stock Exchange, Prime Market 4880
Contact information for inquiries	Katsuji Onishi, Executive Officer and General Manager of Administration Tel: +81-3-6455-5308

CellSource Advances Processing Technology for Contract Processing Services of Adipose-Derived Stem Cells

We are pleased to announce that CellSource Co., Ltd. (the “Company”) will begin offering an updated extraction technology for adipose-derived cultured stem cells as part of our adipose-derived stem cell processing contract service, starting in October.

Under the cultivated cell population, individual cells experience different stress conditions, and some cells may become enlarged and spread out flat. This enlargement of cells is known as one of the typical phenotypes of senescent cells. With this update, we have enhanced the process of extracting cultured stem cells from adipose tissue derived from the same individual, enabling the removal of cells exhibiting such phenotypes.

This technological update was inspired and realized through the process of developing our technology for manufacturing extracellular vesicles, including exosomes. Moving forward, the Company will continue to strive for service updates based on the knowledge gained from our cell and blood processing contract services and collaborative research with various universities and companies.

Note: This translation is for reference purposes only and is not guaranteed to be accurate or complete. In the event of any translation error or misunderstanding, the original Japanese version shall prevail.